2 studies found for:    15475450 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: hLL1-DOX (the doxorubicin conjugate of milatuzumab)
2 Completed Phase I/II Study of hLL1 in Multiple Myeloma
Conditions: Multiple Myeloma;   Myeloma, Plasma-Cell;   PLASMACYTOMA
Intervention: Biological: milatuzumab

Indicates status has not been verified in more than two years